1. Home
  2. CMPX vs JYNT Comparison

CMPX vs JYNT Comparison

Compare CMPX & JYNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.20

Market Cap

927.5M

Sector

Health Care

ML Signal

HOLD

Logo The Joint Corp.

JYNT

The Joint Corp.

HOLD

Current Price

$8.11

Market Cap

138.0M

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMPX
JYNT
Founded
2014
2010
Country
United States
United States
Employees
39
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Multi-Sector Companies
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
927.5M
138.0M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
CMPX
JYNT
Price
$5.20
$8.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
2
Target Price
$14.43
$17.00
AVG Volume (30 Days)
1.7M
59.7K
Earning Date
03-05-2026
03-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
133.93
EPS
N/A
0.19
Revenue
N/A
$117,696,356.00
Revenue This Year
N/A
$3.73
Revenue Next Year
$677.91
$0.78
P/E Ratio
N/A
$42.95
Revenue Growth
N/A
15.49
52 Week Low
$1.33
$7.50
52 Week High
$6.88
$13.47

Technical Indicators

Market Signals
Indicator
CMPX
JYNT
Relative Strength Index (RSI) 37.26 34.99
Support Level $4.86 $7.50
Resistance Level $5.86 $8.77
Average True Range (ATR) 0.29 0.38
MACD -0.02 -0.03
Stochastic Oscillator 15.53 15.50

Price Performance

Historical Comparison
CMPX
JYNT

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.

About JYNT The Joint Corp.

The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.

Share on Social Networks: